<DOC>
	<DOCNO>NCT02981290</DOCNO>
	<brief_summary>This single center , randomize , open label , 4-treatment , 4-period , 4-sequence , 4-way crossover study compare pharmacokinetics mycophenolate mofetil ( MMF ) metabolites 4 tablet formulation healthy participant .</brief_summary>
	<brief_title>Study Compare Pharmacokinetics Mycophenolate Mofetil Metabolites From Four Tablet Formulations Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>A body mass index ( BMI ) 18 32 kilogram per meter square ( kg/m^2 ) Any evidence clinically significant allergic , renal , cardiac , bronchopulmonary , vascular , gastrointestinal , neurological , metabolic immunodeficiency disorder , cancer , hepatitis cirrhosis Any evidence gall bladder surgery , surgery gastrointestinal tract medical condition consider likely affect drug absorption Any major illness within 2 month prior first dose febrile illness within 14 day prior first dose Any known history clinically significant allergic reaction drug hypersensitivity , especially hypersensitivity MMF mycophenolic acid ( MPA ) Any ongoing concomitant disease condition could interfere , treatment might interfere , conduct study , would , opinion investigator , pose unacceptable risk participant Any prescribed overthecounter ( OTC ) medication , herbal medicine dietary aid take within 2 week first study drug dosing within six time elimination halflife medication first study drug dosing</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>